| Dr Douglas Henry Gratwohl, OD | |
|
215 W 3rd Street, Hardin, MT 59034-1701 | |
| (406) 665-1204 | |
| (406) 665-4177 |
| Full Name | Dr Douglas Henry Gratwohl |
|---|---|
| Gender | Male |
| Speciality | Optometry |
| Experience | 46 Years |
| Location | 215 W 3rd Street, Hardin, Montana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1508893694 | NPI | - | NPPES |
| 048-4185 | Medicaid | MT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 431 (Montana) | Primary |
| Provider Name | Shoptikal Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1417513896 PECOS PAC ID: 1456684471 Enrollment ID: O20190617001368 |
News Archive
Doctors have many drugs available to treat multiple myeloma, a type of blood cancer. However, there is no way to predict, by genetic markers or other means, how a patient will respond to a particular drug. This can lead to months of treatment with a drug that isn't working.
What is one of the biggest complaints firefighters have about their job? It's their gloves. While the current gloves are designed to provide protection against extreme temperatures, they are often bulky and inflexible. Through a recent Federal Emergency Management Agency (FEMA) grant, researchers at North Carolina State University will attempt to redesign the traditional firefighter glove to provide fire protection with less bulk and greater hand dexterity.
Scientists have combined two new "designer" forms of aspirin into a hybrid substance that appears more effective than either of its forebears in controlling the growth of several forms of cancer in laboratory tests. Their report on the new NOSH-aspirin, so named because it releases nitric oxide (NO) and hydrogen sulfide (H2S), appears in the journal ACS Medicinal Chemistry Letters.
A multicenter study led by Christian Haass and Michael Ewers of Ludwig-Maximilians-Universitaet in Munich has identified a biomarker associated with the activation of an innate immune response to neural damage during early stages of Alzheimer's disease.
Martinsried-based drug discovery and development company 4SC AG announced today that the US Patent and Trademark Office (ASPTO) has granted the patent with the US patent number 7,176,241 for its drug candidate SC12267.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Douglas Henry Gratwohl, OD 215 W 3rd Street, Hardin, MT 59034-1701 Ph: (406) 665-1204 | Dr Douglas Henry Gratwohl, OD 215 W 3rd Street, Hardin, MT 59034-1701 Ph: (406) 665-1204 |
News Archive
Doctors have many drugs available to treat multiple myeloma, a type of blood cancer. However, there is no way to predict, by genetic markers or other means, how a patient will respond to a particular drug. This can lead to months of treatment with a drug that isn't working.
What is one of the biggest complaints firefighters have about their job? It's their gloves. While the current gloves are designed to provide protection against extreme temperatures, they are often bulky and inflexible. Through a recent Federal Emergency Management Agency (FEMA) grant, researchers at North Carolina State University will attempt to redesign the traditional firefighter glove to provide fire protection with less bulk and greater hand dexterity.
Scientists have combined two new "designer" forms of aspirin into a hybrid substance that appears more effective than either of its forebears in controlling the growth of several forms of cancer in laboratory tests. Their report on the new NOSH-aspirin, so named because it releases nitric oxide (NO) and hydrogen sulfide (H2S), appears in the journal ACS Medicinal Chemistry Letters.
A multicenter study led by Christian Haass and Michael Ewers of Ludwig-Maximilians-Universitaet in Munich has identified a biomarker associated with the activation of an innate immune response to neural damage during early stages of Alzheimer's disease.
Martinsried-based drug discovery and development company 4SC AG announced today that the US Patent and Trademark Office (ASPTO) has granted the patent with the US patent number 7,176,241 for its drug candidate SC12267.
› Verified 5 days ago